Isokinetic microdose exercise for women with fibromyalgia
Effects of a Microdoses Isokinetic Exercise Protocol in Women With Fibromyalgia
This 8-week program will test whether low-dose isokinetic exercise helps women with fibromyalgia reduce pain, improve strength, and enhance quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | European University Miguel de Cervantes Academic / other |
| Locations | 1 site (Valladolid, Valladolid) |
| Trial ID | NCT07483216 on ClinicalTrials.gov |
What this trial studies
The study enrolls adult women with a clinical diagnosis of fibromyalgia to receive an 8-week supervised isokinetic exercise program delivered using microdosing principles to limit intensity and volume. Isokinetic equipment will control movement velocity and joint position to enable safe, precisely dosed muscle contractions. Researchers will measure physical condition (including strength and function), perceived pain, inflammatory biomarkers, and quality of life before and after the intervention. Participants must be clinically and pharmacologically stable and able to attend supervised sessions at the study site.
Who should consider this trial
Good fit: Adult women diagnosed with fibromyalgia who are clinically and pharmacologically stable and able to perform supervised exercise sessions are the ideal candidates.
Not a fit: Men, people with unstable medical conditions or cardiovascular/neurologic/musculoskeletal contraindications to exercise, or those unable to attend supervised sessions are unlikely to receive benefit from participating.
Why it matters
Potential benefit: If successful, this approach could provide a low-intensity, better-tolerated exercise option that reduces pain and improves strength and daily functioning for women with fibromyalgia.
How similar studies have performed: General exercise programs have demonstrated benefits in fibromyalgia, but isokinetic microdosing is a relatively novel approach with limited prior clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged ≥ 18 years diagnosed with fibromyalgia according to current clinical criteria. * Clinical and pharmacological stability during the weeks prior to participation in the study. * Ability to perform supervised exercise and to complete the assessments. * Written informed consent. Exclusion Criteria: * Cardiovascular, neurologic, musculoskeletal or systemic pathology that contraindicate the performance of exercise. * Significant change in pharmacological treatment during the period immediately preceding the study. * Any condition that, in clinical judgement, prevents them from following the protocol safely.
Where this trial is running
Valladolid, Valladolid
- Miguel de Cervantes European University — Valladolid, Valladolid, Spain (Recruiting)
Study contacts
- Principal investigator: Alejandro Santos Lozano, PhD — Miguel de Cervantes European University
- Study coordinator: Alejandro Santos Lozano, PhD
- Email: asantos@uemc.es
- Phone: 0034983001000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.